Make a presentation on post menauposal syndrome with deep research
Asking for Preferences
Reading File
Searching PubMed
postmenopausal syndrome management
Searching the Web
postmenopausal syndrome comprehensive review 2024 symptoms management HRT
Finding Sources
Searching PubMed
menopause hormone therapy cardiovascular risk benefits
Searching PubMed
menopausal vasomotor symptoms hot flashes treatment
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Running Command
Writing File
Running Command
Running Command
Your presentation is ready! Here's the download link:
Postmenopausal Syndrome
Presentation · PPTX
What's Inside (35+ Slides)
The deck uses a bold deep-purple, pink & teal medical color palette, with designed headers, callout boxes, and data tables throughout.
| # | Section | Slides |
|---|---|---|
| 01 | Definition & Terminology (natural, surgical, POI) | 3 |
| 02 | Epidemiology & Global Burden | 1 |
| 03 | STRAW+10 Reproductive Aging Staging | 2 |
| 04 | Pathophysiology: Hormonal changes, KNDy neurons | 3 |
| 05 | Vasomotor Symptoms: classification, impact, SWAN data | 2 |
| 06 | Genitourinary Syndrome of Menopause (GSM) | 2 |
| 07 | Sexual Dysfunction | 2 |
| 08 | Osteoporosis: WHO criteria, full pharmacotherapy table | 3 |
| 09 | Cardiovascular Disease & WHI context | 2 |
| 10 | Neuropsychiatric/Cognitive Changes | 2 |
| 11 | Metabolic & Systemic Effects | 2 |
| 12 | Diagnosis & Differential Diagnosis | 2 |
| 13 | HT Types, Routes, Regimens (full tables) | 4 |
| 14 | HT Benefits/Risks, WHI summary (callout), Contraindications | 3 |
| 15 | Non-Hormonal Pharmacotherapy (fezolinetant 2023) | 2 |
| 16 | Lifestyle, CAM, Phytoestrogens | 2 |
| 17 | Special Populations (POI, breast cancer, CVD, migraine) | 2 |
| 18 | Management Algorithm + Key Take-Aways + References | 3 |
Sources used: Berek & Novak's Gynecology, Goldman-Cecil Medicine, Katzung's Pharmacology, Goodman & Gilman, + 12 recent PubMed systematic reviews/meta-analyses (2021-2026) including the 2024 WHI re-analysis, 2023 fezolinetant FDA approval evidence, and 2025 soy isoflavone meta-analysis.
This is a shared conversation. Sign in to Orris to start your own chat.